|
|
|
Cancer Clinical Trials: Current and Controversial Issues in Design and Analysis |
|
|
|
|
¡ØÇØ¿ÜÁÖ¹® µµ¼ ¾È³» :
- ÇØ¿Ü ¹× ±¹³» ÀÔ°í »çÇ׿¡ µû¶ó 2~8ÁÖ ÀÌ»ó ¼Ò¿äµÉ ¼ö ÀÖÀ¸¸ç. Ãë¼Ò ¹× ¹ÝÇ°ÀÌ ºÒ°¡´ÉÇÕ´Ï´Ù. - ÇØ¿ÜÁÖ¹®µµ¼´Â ÇØ¿Ü ÃâÆÇ»ç »çÁ¤¿¡ ÀÇÇØ Ç°Àý/Áö¿¬µÉ¼ö ÀÖ½À´Ï´Ù. |
|
¡Ø±³È¯ ¹× ¹ÝÇ°¾È³» :
- ±³È¯À̳ª ¹ÝÇ°½Ã »óÇ° ¼ö·ÉÈÄ 3ÀÏÀ̳» ±³È¯À̳ª ¹ÝÇ° Àǻ縦 ¾Ë·ÁÁֽðí ÀÏÁÖÀÏÀ̳»¿¡ ÀúÈñÂÊÀ¸·Î »óÇ°ÀÌ ÀÔ°íµÇ¾î¾ßÇÕ´Ï´Ù. ½ÃÀÏÀÌ °æ°úµÇ¸é ¹ÝÇ°ÀÌ ºÒ°¡ÇÕ´Ï´Ù. - º¯½É¿¡ ÀÇÇÑ ±³È¯À̳ª ¹ÝÇ°½Ã, ¹è¼Ûºñ´Â °í°´´Ô²²¼ ºÎ´ãÇϽøç, ¿À¹è¼ÛÀ̳ª »óÇ° ºÒ·®½Ã¿¡´Â ¹«·á ±³È¯ÀÌ °¡´ÉÇÕ´Ï´Ù. - ¹ÝÇ°½Ã¿¡´Â ¹ÝÇ°»óÇ° °Ë¼öÈÄ Ä«µå Ãë¼Ò¸¦ Çص帮°Å³ª ÅëÀå,Àû¸³±ÝµîÀ¸·Î ȯºÒ Á¶Ä¡ ÇØ µå¸³´Ï´Ù. |
|
¡Ø¹è¼Û¾È³» :
- Á¦ÁÖµµ¹× µµ¼»ê°£Áö¿ªÀº Åùèºñ°¡ Ãß°¡µÉ¼ö ÀÖ½À´Ï´Ù. |
|
|
|
|
|
|
|
|
|
Features
•Presents state-of-the-art approaches to the design and analysis of cancer clinical trials, such as adaptive designs, biomarker-based trials, and dynamic treatment regimes
•Explains the importance of the selection of endpoints, use of historical data, multiplicity, analysis of safety data, discovery and validation of predictive signatures, dose-finding, sample size, and non-inferiority designs
•Includes contributions from top researchers in academia, government, and the industry
•Contains many examples drawn from real cancer clinical trials
Summary
Cancer Clinical Trials: Current and Controversial Issues in Design and Analysis provides statisticians with an understanding of the critical challenges currently encountered in oncology trials. Well-known statisticians from academic institutions, regulatory and government agencies (such as the U.S. FDA and National Cancer Institute), and the pharmaceutical industry share their extensive experiences in cancer clinical trials and present examples taken from actual trials.
The book covers topics that are often perplexing and sometimes controversial in cancer clinical trials. Most of the issues addressed are also important for clinical trials in other settings. After discussing general topics, the book focuses on aspects of early and late phase clinical trials. It also explores personalized medicine, including biomarker-based clinical trials, adaptive clinical trial designs, and dynamic treatment regimes.
|
|
|
|
|
|
General Issues
Endpoints for Cancer Clinical Trials
Stephen L. George, Xiaofei Wang, and Herbert Pang
Use of Historical Data
Simon Wandel, Heinz Schmidli, and Beat Neuenschwander
Multiplicity
Dong Xi, Ekkehard Glimm, and Frank Bretz
Analysis of Safety Data
Steven Snapinn and Qi Jiang
Early Phase Clinical Trials
Development and Validation of Predictive Signatures
Michael C. Sachs and Lisa M. McShane
Phase I Trials and Dose-Finding
Mark R. Conaway and Nolan A. Wages
Design and Analysis of Phase II Cancer Clinical Trials
Sin-Ho Jung
Late Phase Clinical Trials
Sample Size for Survival Trials in Cancer
Edward Lakatos
Non-Inferiority Trials
Rajeshwari Sridhara and Thomas Gwise
Quality of Life
Diane Fairclough
Personalized Medicine
Biomarker-Based Clinical Trials
Edward L. Korn and Boris Freidlin
Adaptive Clinical Trial Designs in Oncology
J. Jack Lee and Lorenzo Trippa
Dynamic Treatment Regimes
Marie Davidian, Anastasios (Butch) Tsiatis, and Eric Laber
Index |
|
|
|
|
|
|
|
|
µî·ÏµÈ ¼ÆòÀÌ ¾ø½À´Ï´Ù. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|